Loading...
01/11 14:02
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals strong financial metrics, including a significant improvement in net loss and cash burn guidance, alongside positive developments like the partnership with Athena Health and commercial launch in Israel. Despite some uncertainties in international plans and NHS Galleri study specifics, the overall sentiment remains positive due to the strategic focus on growth and cost management. The Q&A section reinforces this with management's confidence in revenue growth and operational efficiencies. Given these factors, a positive stock price movement of 2% to 8% is expected.
Revenue for Q2 2025 $35.5 million, up $3.5 million or 11% year-over-year. The increase was driven by strong demand for the Galleri test, with more than 45,000 tests sold in the quarter.
Screening Revenue for Q2 2025 $34.4 million, up 22% year-over-year. U.S. Galleri revenue was $34.2 million, up 21% compared to the second quarter last year. The growth was attributed to increased test volumes and repeat testing.
Development Services Revenue for Q2 2025 $1.1 million. This includes services provided to biopharmaceutical and clinical customers, such as support for clinical studies, pilot testing, research, and therapy development.
Net Loss for Q2 2025 $114 million, an improvement of 93% year-over-year. The improvement was due to reduced cash burn and cost management, despite including impairment of Illumina acquisition-related intangible assets of $28 million and stock-based compensation of $14.2 million.
Non-GAAP Adjusted Gross Profit for Q2 2025 $16.1 million, an increase of $0.1 million or 1% year-over-year. The increase was driven by reduced variable costs of Galleri testing performed on the automated platform, offset by a 6% decrease in ASP and additional sample reprocessing costs.
Cash Position at the end of Q2 2025 $606.1 million. The company updated its guidance for cash burn to no more than $310 million for the full year 2025, representing a decrease of more than 40% compared to 2024.
Galleri test orders: More than 45,000 Galleri commercial tests sold in Q2 2025, with over 370,000 tests prescribed since 2021 by more than 15,000 healthcare providers.
New Galleri version: A new version of Galleri with an industrial-scale platform and significant automation was introduced in late 2024 to scale efficiently with future demand.
Partnerships: Established partnerships with healthcare systems, including Rush University System for Health, the first in the Chicago area to offer Galleri.
Collaboration: Entered a collaboration with Everlywell, making Galleri available for requests directly on Everlywell's website via prescription.
Automation and efficiency: The new Galleri version incorporates significant automation to scale efficiently, though some issues with turnaround times and reprocessing costs were noted.
Revenue growth: Q2 2025 revenue was $35.5 million, up 11% from Q2 2024, with screening revenue up 22% year-over-year.
Regulatory milestones: Plans to submit detailed results from PATHFINDER 2 study to ESMO Congress 2025 and complete modular PMA submission to FDA in H1 2026.
Long-term goals: Focus on achieving FDA approval and broad reimbursement for Galleri, with key clinical and regulatory milestones planned for 2025 and 2026.
Supply Chain Disruptions: The company has experienced increased turnaround times and higher reprocessing costs for a small proportion of samples due to the scale and complexity of the new version of Galleri. This indicates potential supply chain or operational inefficiencies.
Regulatory Hurdles: The company is pursuing FDA approval for Galleri and broad reimbursement, which are critical for its strategic objectives. Any delays or challenges in obtaining these approvals could impact its operations and market access.
Economic Uncertainties: The company reported a net loss of $114 million for the quarter, though it has improved compared to the previous year. This financial loss, coupled with cash burn guidance of $310 million for the year, highlights economic pressures.
Operational Challenges: The implementation of a new automated platform for Galleri testing has led to increased sample reprocessing costs and operational inefficiencies, which could affect scalability and profitability.
Market Conditions: While demand for Galleri tests is growing, the company faces seasonal fluctuations in test volumes, which could impact revenue consistency.
Commercial Growth: The company remains on track for continued commercial growth in 2025, driven by increasing Galleri test volumes and partnerships with health systems like Rush University System for Health and Everlywell.
Galleri Test Enhancements: A new version of the Galleri test, incorporating an industrial-scale platform with significant automation, is being used to scale efficiently with future demand. Fixes are being implemented to address increased turnaround times and higher reprocessing costs for a small proportion of samples.
Regulatory Milestones: The company plans to submit detailed performance and safety results from the PATHFINDER 2 study at the ESMO Congress 2025 in October. Additionally, a modular PMA submission to the FDA is expected in the first half of 2026.
Clinical Utility Data: Full clinical utility results from the 140,000-participant NHS Galleri study are expected to read out mid-2026. This data will be reviewed by the NHS to determine Galleri's potential deployment within the U.K. population.
Financial Guidance: The company has updated its cash burn guidance for 2025 to no more than $310 million, a decrease of over 40% compared to 2024. The cash runway extends into 2028, supporting major clinical and regulatory milestones.
The selected topic was not discussed during the call.
The earnings call reveals strong financial performance with a 69% increase in gross profit and a 14% rise in gross margin. The company has a robust cash position of $850 million, excluding a pending investment from Samsung. Despite some uncertainties, such as the impact of a $150 promotion, the company's strategic partnerships and growth in test volumes indicate a positive outlook. The updated FDA timeline and improved cost efficiencies further support a positive sentiment, suggesting a likely stock price increase over the next two weeks.
The earnings call reveals strong financial metrics, including a significant improvement in net loss and cash burn guidance, alongside positive developments like the partnership with Athena Health and commercial launch in Israel. Despite some uncertainties in international plans and NHS Galleri study specifics, the overall sentiment remains positive due to the strategic focus on growth and cost management. The Q&A section reinforces this with management's confidence in revenue growth and operational efficiencies. Given these factors, a positive stock price movement of 2% to 8% is expected.
Despite regulatory and competitive risks, GRAIL's strong financial performance, reduced cash burn, and extended cash runway are positive indicators. Revenue growth and improved margins suggest operational efficiency. The Q&A session reveals optimism about cost improvements and market expansion. While management was vague on some cost details, the overall sentiment is positive, with a focus on achieving major milestones. The company's financial health and strategic focus on growth and efficiency are likely to lead to a positive stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
